Retraction of: Cancer Gene Therapy https://doi.org/10.1038/s41417-018-0068-4, published online 01 February 2019
The Editor-in-Chief has retracted this article at the authors’ request. After publication, the authors noticed that incorrect images were used in Fig. 2E to inform their conclusions. The authors therefore no longer have confidence in the presented results and data reproducibility.
ZY and XJ agree to this retraction. SY and HY have not responded to any correspondence from the editor or publisher about this retraction. The Editor has not been able to obtain a current email address for HZ.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41417-018-0068-4.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yao, Z., Yang, S., Zhao, H. et al. Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction. Cancer Gene Ther 29, 1528 (2022). https://doi.org/10.1038/s41417-022-00536-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41417-022-00536-4
